hrp0084p2-468 | Growth | ESPE2015

Novel Heterozygous ACAN Mutations in Short Stature: Expanding the Clinical Spectrum

Sentchordi Lucia , Barraza Jimena , Rivera Carlos Ivan , Marcos M. Victoria , Sanchez M. Consuelo , Vallespin Elena , Pozo Angela del , Heath Karen E.

Background: Homozygous aggrecan (ACAN) mutations have been described in a few skeletal dysplasias whilst more recently, heterozygous ACAN mutations have been reported in few families presenting with idiopathic short stature with advanced bone maturation and premature growth cessation.Case presentation: We describe two novel heterozygous ACAN stop mutations, detected using a skeletal dysplasia NGS panel and confirmed by Sanger sequencing...

hrp0092p1-17 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Serum Testosterone Level at the Age of 12 is an Important Determinant of the Following Gain of Bone Mineral Apparant Density in 18-year Old Males: a Longitudinal Study From Puberty

Tamme Reeli , Jürimäe Jaak , Remmel Liina , Mäestu Evelin , Purge Priit , Mengel Eva , Tillmann Vallo

Background: Many cross-sectional studies have demonstrated that serum testosterone concentration is an important biochemical predictor of bone mineral density in young males, but to our knowledge, no longitudinal studies have been carried out to support these cross-sectional data.Aims: to examine the associations between serum testosterone concentration at the age of 12 and the following gain in bone mineral density unti...

hrp0094fc5.1 | Sex Development and Gender Incongruence | ESPE2021

Growth and growth reduction in transgirls

Boogers Lidewij S , Wiepjes Chantal M , Hellinga Ilse , Klink Daniel T , den Heijer Martin , Hannema Sabine E ,

Introduction: Little is known about the effects of puberty suppression (PS) and hormone therapy (HT) on growth and adult height in transgender adolescents. These are topics of interest since height differs between sexes and some transgirls wish to limit their growth. In this longitudinal cohort study, we investigated the influence of PS and HT on growth and the efficacy of growth reduction therapy in transgender girls.Methods:</s...

hrp0094p1-62 | Diabetes B | ESPE2021

Epidemiology of type 1 diabetes in children and adolescents: a 50-year, single center experience

Vuralli Dogus , Ozon Z. Alev , Gonc E. Nazli , Ardicli Didem , Jalilova Lala , Gulcek Omer Nazım , Alikasifoglu Ayfer ,

Introduction: Global variations in epidemiology of type 1 diabetes (T1D) exist worldwide. This study is designed to determine the demographic and clinical characteristics of T1D in the past three decades, and to analyze changing trends in epidemiology over the past 50 years.Methods: Epidemiological and clinical characteristics of 925 patients with T1D were analyzed in three decades between 1991 and 2019. In addition, pre...

hrp0086p2-p278 | Diabetes P2 | ESPE2016

Childhood Type 1 Diabetes (T1D) Management with e-learning through Self-educational Tools

Bibal Cecile , Laure Castell Anne , Aboumrad Brigitte , Lucchini Philippe , Bougneres Pierre

Background: Children with type 1 diabetes (T1D) and their parents need personalized i) information about the disease and glucose homeostasis and ii) knowledge and guidelines about diet and insulin therapy.Objectives: To set a complete educational program that allows children with T1D to improve disease management and daily life.Methods: Education modules were written and trained with children and parents at outpatient visits. Each ...

hrp0094p2-234 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism

Hood Davelyn E. , Roberts Brian K. , Neale Ann , Raskin Julie ,

Introduction: Congenital Hyperinsulinism (CHI) is the most frequent cause of severe, persistent hypoglycemia in children. Despite current treatments, patients/caregivers report continued hypoglycemia according to the HI Global Registry 2020 Annual Report. Published literature characterizing hypoglycemia in CHI patients on standard of care (SOC) therapies is lacking.Objective: To quantify the extent of hypoglycemia in CHI...

hrp0082p1-d1-147 | Growth | ESPE2014

The Role of SHOX Gene in Idiopathic Short Stature: an Italian Multicenter Study

Minari R , Vottero A , Azzolini S , Barbaro D , Bindi G , Bozzola M , Burrai C , Cardinale G M , Cioffi D , Cisternino M , Coccioli M S , Delvecchio M , Fabbrizi E , Ferrari M , Gallarotti F , Gallo F , Ghizzoni L , Maggio M C , Mainetti B , Montinaro R , Municchi G , Panariello A , Parpagnoli M , Perrone L , Petraroli M , Radetti G , Radicioni A F , Rossodivita A , Salerno MC , Savasta S , Seminara S , Tafi L , Tomat M , Tummolo A , Wasniewska M , Iughetti L , Bernasconi S

Background: The short stature homeobox-containing (SHOX) gene, located in the telomeric pseudoautosomal region 1 (PAR1) on the short arm of both sex chromosomes, is important for linear growth.Objective and hypotheses: The aim of our study was to evaluate the presence of SHOX gene deletions/point mutations in children with short stature in order to understand the role of SHOX gene in idiopathic short stature (ISS) and estimate its frequency.<p class=...

hrp0084p2-406 | GH &amp; IGF | ESPE2015

Metabolic Health in Short Children Born Small for Gestational Age Treated with GH and GnRHa: Results of a Randomised, Dose-response Trial

van der Steen M , Lem A J , van der Kaay D C M , Waarde W M Bakker-van , van der Hulst F J P C M , Neijens F S , Noordam C , Odink R J , Oostdijk W , Schroor E J , Sulkers E J , Westerlaken C , Hokken-Koelega A C S

Background: Previously we showed that pubertal children born small for gestational age (SGA) with a poor adult height (AH) expectation can benefit from treatment with GH 1 mg/m2 per day (~0.033 mg/kg per day) in combination with 2 years of GnRH analogue (GnRHa) and even more so with a double GH dose. GnRHa treatment is thought to have negative effects on body composition and blood pressure. Long-term effects and GH-dose effects on metabolic health in children treate...

hrp0084fc8.2 | Obesity - Basic | ESPE2015

Apoptosis Inhibitor of Macrophages: an Anti-Inflammatory Adipocyte Factor in Mild Adolescent Obesity?

Karvela Alexia , Avgeri Aikaterini , Vlotinou Eleni D , Georgiou George , Papaxristou Dionysios , Miyazaki Toru , Spiliotis Bessie E

Background: Adipose tissue (AT) in obesity is characterized by low grade inflammation. The apoptosis inhibitor of macrophages (AIM; also called CD5L) is incorporated into adipocytes leading to increased lipolysis. Excess AIM-dependent lipolysis induces adipose tissue macrophage recruitment. M1 (proinflammatory) macrophage infiltration, with surface marker CD40, correlates with metabolic complications.Objective and hypotheses: To study serum levels and AT...

hrp0089p1-p015 | Adrenals and HPA Axis P1 | ESPE2018

New Insights into Low Dose Dexamethasone Suppression Test in Paediatric Cushing’s Syndrome

Wilkinson Ingrid C E , Martin Lee , Grossman Ashley B , Monson John P , Akker Scott , Savage Martin O , Drake William M , Storr Helen L

Background: The Low dose dexamethasone suppression test (LDDST) is an important investigation for suspected Cushing’s Syndrome (CS). The traditional definition of normal suppression of serum cortisol to ≤50 nmol/l during the LDDST (0.5 mg 6 hrly × 48 h) comes from a time when biochemical autoanalysers did not routinely detect very low values. Previous studies reported 5.1–8.3% of patients with Cushing’s Disease (CD) suppressed to <50 nmol/l at 48 ...